Sunitinib, Malate Salt 5g
To Order Contact us: lieven@wlsolutions.be
Sunitinib malate |
||
| A8255-1000 | 1 g | EUR 268.8 |
|
Description: Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor and RET kinase [2][3] [4]. |
||
Sunitinib malate |
||
| A8255-2000 | 2 g | EUR 338.4 |
|
Description: Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor and RET kinase [2][3] [4]. |
||
Sunitinib malate |
||
| A8255-5.1 | 10 mM (in 1mL DMSO) | EUR 135.6 |
|
Description: Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor and RET kinase [2][3] [4]. |
||
Sunitinib malate |
||
| A8255-500 | 500 mg | EUR 199.2 |
|
Description: Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor and RET kinase [2][3] [4]. |
||
Sunitinib malate |
||
| A8255-S | Evaluation Sample | EUR 97.2 |
|
Description: Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor and RET kinase [2][3] [4]. |
||
Sunitinib malate |
||
| GP2160-100MG | 100 mg | EUR 180 |
Sunitinib malate |
||
| GP2160-10MG | 10 mg | EUR 93.6 |
Sunitinib malate |
||
| GP2160-50MG | 50 mg | EUR 122.4 |
Sunitinib malate |
||
| GP2160-10 | 10 | EUR 47.4 |
Sunitinib malate |
||
| GP2160-100 | 100 | EUR 118.7 |
Sunitinib malate |
||
| GP2160-50 | 50 | EUR 71.1 |
Sunitinib Malate (Sutent) |
||
| 1611-100 | each | EUR 248.4 |
Sunitinib Malate (Sutent) |
||
| 1611-1000 | each | EUR 614.4 |
Sunitinib Malate (Sutent) |
||
| 1611-25 | each | EUR 151.2 |
EZSolution? Sunitinib Malate |
||
| 1804-25 | each | EUR 164.4 |
Sunitinib malate (VEGFR, PDGFR kinase inhibitor) |
||
| SIH-482-25MG | 25 mg | EUR 582 |
|
Description: The substance Sunitinib malate is a vegfr, pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in DMSO (40 mg/ml). |
||
Sunitinib malate (VEGFR, PDGFR kinase inhibitor) |
||
| SIH-482-5MG | 5 mg | EUR 198 |
|
Description: The substance Sunitinib malate is a vegfr, pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in DMSO (40 mg/ml). |
||
Sunitinib |
||
| B1045-100 | 100 mg | EUR 129.6 |
|
Description: Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFR? and PDGFR? ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). |
||
Sunitinib |
||
| B1045-1000 | 1 g | EUR 268.8 |
|
Description: Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFR? and PDGFR? ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). |
||
Sunitinib |
||
| B1045-2000 | 2 g | EUR 338.4 |
|
Description: Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFR? and PDGFR? ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). |
||
Sunitinib |
||
| B1045-5.1 | 10 mM (in 1mL DMSO) | EUR 135.6 |
|
Description: Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFR? and PDGFR? ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). |
||
Sunitinib |
||
| B1045-500 | 500 mg | EUR 199.2 |
|
Description: Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFR? and PDGFR? ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). |
||
Sunitinib |
||
| HY-10255A | 200mg | EUR 192 |
Sunitinib-D4 |
||
| 20-abx184388 |
|
|
Sunitinib (Sutent) |
||
| E1KS1042 | 300mg | EUR 296.4 |
Sunitinib, Free base |
||
| 2097-100 | each | EUR 229.2 |
Sunitinib, Free base |
||
| 2097-1000 | each | EUR 601.2 |
Sunitinib, Free base |
||
| 2097-25 | each | EUR 138 |
N-Desethyl Sunitinib |
||
| HY-10873 | 10mg | EUR 639.6 |
Pizotifen Malate |
||
| B2007-100 | 100 mg | EUR 139.2 |
|
Description: Pizotifen malate is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug. |
||
Pizotifen Malate |
||
| B2007-300 | 300 mg | EUR 217.2 |
|
Description: Pizotifen malate is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug. |
||
Pizotifen Malate |
||
| B2007-5.1 | 10 mM (in 1mL DMSO) | EUR 129.6 |
|
Description: Pizotifen malate is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug. |
||
Pizotifen Malate |
||
| B2007-500 | 500 mg | EUR 258 |
|
Description: Pizotifen malate is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug. |
||
Pizotifen (malate) |
||
| HY-B0115A | 200mg | EUR 192 |
Clebopride Malate |
||
| 20-abx186414 |
|
|
Vicriviroc Malate |
||
| 1599-1 | each | EUR 464.4 |
Vicriviroc Malate |
||
| 1599-5 | each | EUR 1286.4 |
Vicriviroc Malate |
||
| A2589-10 | 10 mg | EUR 448.8 |
|
Description: Vicriviroc is an inhibitor of CCR5 signaling with IC50 value of 0.91nM [1].The ?rst step of HIV-1 infection is that the viral envelope, gp120, will interact with cellular coreceptor CCR5. |
||
Vicriviroc Malate |
||
| A2589-5 | 5 mg | EUR 268.8 |
|
Description: Vicriviroc is an inhibitor of CCR5 signaling with IC50 value of 0.91nM [1].The ?rst step of HIV-1 infection is that the viral envelope, gp120, will interact with cellular coreceptor CCR5. |
||
Vicriviroc Malate |
||
| A2589-5.1 | 10 mM (in 1mL DMSO) | EUR 505.2 |
|
Description: Vicriviroc is an inhibitor of CCR5 signaling with IC50 value of 0.91nM [1].The ?rst step of HIV-1 infection is that the viral envelope, gp120, will interact with cellular coreceptor CCR5. |
||
Vicriviroc Malate |
||
| A2589-50 | 50 mg | EUR 756 |
|
Description: Vicriviroc is an inhibitor of CCR5 signaling with IC50 value of 0.91nM [1].The ?rst step of HIV-1 infection is that the viral envelope, gp120, will interact with cellular coreceptor CCR5. |
||
Clebopride (malate) |
||
| HY-B1613A | 100mg | EUR 472.8 |
Almotriptan Malate |
||
| B2243-10 | 10 mg | EUR 129.6 |
|
Description: Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affin |
||
Almotriptan Malate |
||
| B2243-100 | 100 mg | EUR 505.2 |
|
Description: Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affin |
||
Almotriptan Malate |
||
| B2243-5.1 | 10 mM (in 1mL DMSO) | EUR 129.6 |
|
Description: Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affin |
||
Almotriptan Malate |
||
| B2243-S | Evaluation Sample | EUR 97.2 |
|
Description: Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affin |
||
Cabozantinib malate |
||
| GP4726-1 | 1 | EUR 1138.9 |
Cabozantinib malate |
||
| GP4726-100 | 100 | EUR 197.7 |
Cabozantinib malate |
||
| GP4726-500 | 500 | EUR 702.7 |
Malate dehydrogenase |
||
| 44R-1079 | 100 KU | EUR 159.6 |
|
Description: Malate dehydrogenase enzyme |
||
Malate Assay Kit |
||
| 55R-1478 | 100 assays | EUR 807.6 |
|
Description: Assay Kit for detection of Malate in the research laboratory |
||
Malate dehydrogenase (MDH) |
||
| M0373 | 25KU | EUR 208.78 |
Cabozantinib malate (XL184) |
||
| B1401-100 | 100 mg | EUR 1005.6 |
|
Description: Cabozantinib malate is a potent inhibitor of MET andVEGF receptor2 with IC50 values of 1.3nM and 0.035nM [1]. |
||
Cabozantinib malate (XL184) |
||
| B1401-25 | 25 mg | EUR 338.4 |
|
Description: Cabozantinib malate is a potent inhibitor of MET andVEGF receptor2 with IC50 values of 1.3nM and 0.035nM [1]. |
||
Cabozantinib malate (XL184) |
||
| B1401-5 | 5 mg | EUR 157.2 |
|
Description: Cabozantinib malate is a potent inhibitor of MET andVEGF receptor2 with IC50 values of 1.3nM and 0.035nM [1]. |
||
Cabozantinib malate (XL184) |
||
| B1401-5.1 | 10 mM (in 1mL DMSO) | EUR 199.2 |
|
Description: Cabozantinib malate is a potent inhibitor of MET andVEGF receptor2 with IC50 values of 1.3nM and 0.035nM [1]. |
||
Malate Dehydrogenase (Recombinant) |
||
| 20-abx073339 |
|
|
IC Anion Std Malate 1000ppm in H2O |
||
| ICAB22 | 500ML | EUR 316.8 |
Malate Colorimetric Assay Kit |
||
| K637-100 | each | EUR 588 |
Malate Colorimetric Assay Kit |
||
| K2139-100 | 100 assays | EUR 602.4 |
Malate dehydrogenase 1 Antibody |
||
| R34984-100UG | 100 ug | EUR 339.15 |
|
Description: Additional name(s) for this target protein: MDHA, MOR2; MDH1 |
||
EnzyChrom™ Malate Assay Kit |
||
| EMAL-100 | 100 | EUR 419 |
|
Description: For quantitative determination of L-malate (L-malic acid) and drug effects on malate metabolism. Key Features: Fast and sensitive. Use of 20 µL sample. Linear detection range 0.02 to 2 mM L-malate in 96-well plate assay. Convenient. The procedure involves adding a single working reagent, and reading the optical density at time 15 minutes. Room temperature assay. No 37°C heater is needed. High-throughput. Can be readily automated as a high-throughput 96-well plate assay for thousands of samples per day. Method: OD565nm. Samples: Malate in food, juice, beverage and other agricultural products. Species: All. Procedure: Assay takes 15 min. Kit size: 100 tests. Detection limit: 0.02 mM. |
||
Malate Dehydrogenase 1 (Recombinant) |
||
| abx073926-50000IU | 50.000 IU | EUR 1612.8 |
Malate Dehydrogenase 1 (Recombinant) |
||
| abx073926-5000IU | 5000 IU | EUR 393.6 |
Malate Dehydrogenase 1 (Recombinant) |
||
| 20-abx073502 |
|
|
Malate Dehydrogenase 2 (Recombinant) |
||
| 20-abx073623 |
|
|
Malate Dehydrogenase 1 (Recombinant) |
||
| abx073926-1000IU | 1000 IU | EUR 276 |
Recombinant Malate Dehydrogenase 1 |
||
| 7-03112 | 1000IU | Ask for price |
Recombinant Malate Dehydrogenase 1 |
||
| 7-03113 | 5000IU | Ask for price |
Recombinant Malate Dehydrogenase 1 |
||
| 7-03114 | 50,000IU | Ask for price |
Malate Synthase G (GLCB) Antibody |
||
| 20-abx300792 |
|
|
Recombinant (E.Coli) Malate Dehydrogenase |
||
| RP-362 | 1000 IU | EUR 196.8 |
Malate Dehydrogenase Recombinant Protein |
||
| 91-256 | 0.05 mg | EUR 852.9 |
|
Description: Malate Dehydrogenase, Cytoplasmic (MDH1) is an enzyme which belongs to the MDH Type 2 sub-family of LDH/MDH superfamily. MDH1 is involved in the Citric Acid Cycle that catalyzes the conversion of Malate into Oxaloacetate (using NAD+) and vice versa. MDH1 should not be confused with Malic Enzyme, which catalyzes the conversion of Malate to Pyruvate, producing NADPH. MDH1 also participates in Gluconeogenesis, the synthesis of Glucose from smaller molecules. Pyruvate in the mitochondria is acted upon by Pyruvate Carboxylase to form Pxaloacetate, a Citric Acid Cycle intermediate. In order to transport the Oxaloacetate out of the Mitochondria, Malate Dehydrogenase reduces it to Malate, and it then traverses the inner Mitochondrial membrane. Once in the cytosol, the Malate is oxidized back to Oxaloacetate by MDH1. Finally, Phosphoenol-Pyruvate Carboxy Kinase (PEPCK) converts Oxaloacetate to Phosphoenol Pyruvate. |
||
Malate dehydrogenase Recombinant Protein |
||
| 92-353 | 0.05 mg | EUR 852.9 |
|
Description: Malate dehydrogenase, mitochondrial is a 338 amino acids protein that belongs to the LDH/MDH superfamily. MDH type 1 family. MDH2 catalyzes the reversible oxidation of malate to oxaloacetate, utilizing the NAD/NADH cofactor system in the citric acid cycle. MDH2 is localized to the mitochondria and takes part in the malate-aspartate shuttle that functions in the metabolic coordination between cytosol and mitochondria. MDH2 is highly expressed in the adrenal system, small intestine, heart and pancreas. |
||
Native Microorganism Malate Dehydrogenase |
||
| DIA-160 | 10KU | EUR 583.2 |
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| abx235073-100ug | 100 ug | EUR 577.2 |
Malate Dehydrogenase 2 (MDH2) Antibody |
||
| abx235074-100ug | 100 ug | EUR 577.2 |
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| 20-abx242292 |
|
|
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| 20-abx173445 |
|
|
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| 20-abx173446 |
|
|
Malate Dehydrogenase 2 (MDH2) Antibody |
||
| 20-abx173447 |
|
|
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| 20-abx177444 |
|
|
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| 20-abx214284 |
|
|
Malate Dehydrogenase 1 (MDH1) Antibody |
||
| 20-abx322108 |
|
|
Malate Dehydrogenase 2 (MDH2) Antibody |
||
| 20-abx322256 |
|
|